西地那非联合硫酸镁治疗新生儿持续性肺动脉高压效果分析

Effect of Sildenafil Combined with Magnesium Sulfate on Persistent Pulmonary Hypertension in Newborns

目的分析西地那非联合硫酸镁治疗新生儿持续性肺动脉高压效果分析。方法选择2018年2月—2019年2月该院收治新生儿持续性肺动脉高压患儿98例临床资料,按随机数表分为两组,对照组49例采用硫酸镁治疗,研究组49例在对照组基础上添加西地那非治疗,对两组治疗效果、临床相关指标及不良反应进行比较。结果研究组总有效93.88%,高于对照组,差异有统计学意义(χ~2=4.346,P<0.05);研究组PaO_2(85.93±3.23)mmHg高于对照组;研究组PaCO_2(36.14±3.13)mmHg及SPAP (24.14±3.16)mmHg比对照组低(t=10.864、14.984、17.697,P<0.05);研究组患儿心动过速、便秘等不良反应率低于对照组(χ~2=4.404,P<0.05)。结论西地那非联合硫酸镁治疗新生儿持续性肺动脉高压,能改善新生儿各项指标,减少不良反应发生,还能提升其治疗效果。

Objective To analyze the effect of sildenafil combined with magnesium sulfate in the treatment of neonatal persistent pulmonary hypertension.Methods From February 2018 to February 2019,98 clinical data of neonates with persistent pulmonary hypertension in the hospital were selected and divided into two groups according to the random number table.The control group was treated with magnesium sulfate,and the study group was treated with magnesium sulfate.The control group was added with sildenafil to compare the treatment effects,clinically relevant indicators and adverse reactions between the two groups.Results The total effectiveness of the study group was 93.88%,which was higher than that of the control group,and the difference was statistically significant(χ2=4.346,P<0.05).The PaO2(85.93±3.23)mmHg of the research group was higher than that of the control group;PaCO2(36.14±3.13)mmHg of the research group.And SPAP(24.14±3.16)mmHg was lower than that of the control group(t=10.864,14.984,17.697,P<0.05);the adverse reaction rate of tachycardia and constipation in the study group was lower than that in the control group(χ2=4.404,P<0.05).Conclusion Sildenafil combined with magnesium sulfate in the treatment of persistent pulmonary hypertension in neonates can improve various indicators of neonates,reduce the incidence of adverse reactions,and enhance its therapeutic effect.